

Neoplasms Cancer

A Roll Over Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Trial Status
Recruiting

Trial Runs In
8 Countries

Trial Identifier
NCT03194893 2017-000207-24
BO39694

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study is to provide continued treatment with alectinib or crizotinib as applicable to participants with ALK- or RET positive cancer who were previously enrolled in any Roche-sponsored alectinib study and who are deriving continued clinical benefit from alectinib or crizotinib in the parent trial at the time of parent trial closure.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT03194893 2017-000207-24 BO39694
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
All

Healthy Volunteers
No
